ストックスクリーナーアプリを入手
4.04
3.06%
0.12
アフターアワーズ：
4.06
0.02
+0.50%
前日終値:
$3.92
開ける：
$3.95
24時間の取引高:
16,999
Relative Volume:
0.20
時価総額：
$37.41M
収益：
$4.01M
当期純損益:
$-26.97M
株価収益率:
-1.3599
EPS:
-2.9707
ネットキャッシュフロー:
$-23.45M
1週間 パフォーマンス:
-4.72%
1か月 パフォーマンス:
-7.97%
6か月 パフォーマンス:
-48.34%
1年 パフォーマンス:
-54.35%
1日の値動き範囲:
$3.907
$4.17
1週間の範囲:
$3.78
$4.4384
52週間の値動き範囲:
$3.58
$14.00
Cervomed Inc Stock (CRVO) Company Profile
Compare CRVO vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
4.04 | 36.29M | 4.01M | -26.97M | -23.45M | -2.9707 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-13 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-12-05 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-18 | 開始されました | Chardan Capital Markets | Buy |
| 2024-07-26 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-15 | 開始されました | Canaccord Genuity | Buy |
| 2020-11-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cervomed Inc (CRVO) 最新ニュース
CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB) - Insider Monkey
CEO Change: Is CervoMed Inc stock overvalued or fairly priced2026 Technicals & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Top 5 Stocks Under $5 That Could Triple - Insider Monkey
CervoMed Posts Investor Presentation Under Regulation FD Disclosure - TipRanks
CRVO: Phase III DLB trial launches this year, leveraging biomarker-driven selection and robust phase II data - TradingView
CervoMed (NASDAQ: CRVO) furnishes updated investor presentation via 8-K - Stock Titan
CervoMed reports Phase 2b trial data for DLB treatment neflamapimod By Investing.com - Investing.com India
CervoMed Presents New Data Reinforcing Positive Effects of Tuvapimod in Dementia with Lewy Bodies Without Alzheimer’s Co-Pathology at AD/PD 2026 Conference - Minichart
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results - TipRanks
[8-K] CervoMed Inc. Reports Material Event | CRVO SEC FilingForm 8-K - Stock Titan
CervoMed (CRVO): Analyst Maintains Buy Rating with $31 Price Tar - GuruFocus
CervoMed (CRVO) Showcases Promising Trial Results for Neflamapim - GuruFocus
CervoMed Inc Announces New Data on Neflamapimod In Dementia With Lewy Bodies - marketscreener.com
CervoMed reports Phase 2b trial data for DLB treatment neflamapimod - Investing.com
CervoMed Inc. unveils new analyses linking better neflamapimod outcomes to reduced Alzheimer co-pathology - Traders Union
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology - The Manila Times
CRVO: Roth Capital Lowers Price Target, Maintains Buy Rating | C - GuruFocus
CervoMed (CRVO): Chardan Capital Raises Price Target to $21.00 | - GuruFocus
Market Trends: Is CervoMed Inc currently under institutional pressureDollar Strength & Smart Money Movement Tracker - baoquankhu1.vn
CervoMed Reports 2025 Results, Advances Neflamapimod Programs - TipRanks
CRVO: Phase 3 DLB trial planned for H2 2026, with cash runway limited to six months - TradingView
CervoMed (CRVO) widens 2025 loss as cash runway falls to six months - Stock Titan
Aug Macro: Is CervoMed Inc stock overvalued or fairly pricedWeekly Trading Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
H.C. Wainwright reiterates CervoMed stock rating on conference data By Investing.com - Investing.com India
H.C. Wainwright reiterates CervoMed stock rating on conference data - Investing.com
CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Updates - TradingView
CervoMed Inc. Reports Positive Phase 2b Clinical Data and Plans for Phase 3 Trial in Dementia with Lewy Bodies - Quiver Quantitative
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - ChartMill
Dementia drug CervoMed readies 2026 trials on six‑month cash runway - Stock Titan
CervoMed (CRVO) Maintains Current Analyst Ratings and Price Targ - GuruFocus
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs - The Globe and Mail
CervoMed Inc. (CRVO) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com
CervoMed Inc. Annual Report 2025: Strategy, Key Terms, and Forward-Looking Statements for Age-Related Brain Disorders - Minichart
CervoMed 10-K: $4.01M Grant Revenue; Net Loss $26.97M, $(2.98) EPS - TradingView
CRVO: Neflamapimod achieved robust, durable efficacy in DLB without AD co-pathology, advancing to Phase 3 - TradingView
CRVO: Net loss widened to $27.0 million in 2025; ongoing operations depend on new capital - TradingView
CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CervoMed Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference - Sahm
CervoMed (CRVO) to Showcase Neflamapimod Advancements at AD/PD 2 - GuruFocus
CervoMed Announces Presentations at Upcoming AD/PD 2026 Scientific Conference - Bitget
CervoMed Inc neflamapimod selected by UK platform for ALS treatment assessment - Traders Union
Is CervoMed Inc. stock a good choice for value investorsWeekly Gains Report & Short-Term Trading Opportunity Alerts - Naître et grandir
CervoMed to Participate in Upcoming Investor Conferences - Sahm
Analysts Are Bullish on These Healthcare Stocks: Senseonics Holdings (SENS), OmniAb (OABI) - The Globe and Mail
D. Boral Capital Reaffirms Buy Rating for CervoMed (NASDAQ:CRVO) - Defense World
Chardan Capital Maintains Buy Rating for CRVO | CRVO Stock News - GuruFocus
CervoMed sets 50mg dose for phase 3 dementia trial By Investing.com - Investing.com Canada
CervoMed Finalizes Formulation and Dosing Regimen for Phase 3 Trial in Dementia with Lewy Bodies - geneonline.com
CervoMed Advances Neflamapimod With Phase 1 Completion - TipRanks
Cervomed Inc (CRVO) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):